3 years 45.5
Extreme 45.5
131.98
5 years 34.43
Extreme 34.43
131.98
10 years 6.75
Extreme 6.75
131.98
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 01/04/2022
Compliance Officer 64 02/07/2019
Corporate Secretary - -
Date Insider Type Main position Quantity % Market Cap. Importance
02/04/25 Issuer saleCompany 10,000 0.0094%
02/04/25 Issuer sale

Director

55,511 0.0522%
02/04/25 Issuer sale

Chief Technology Officer

2,65,944 0.2501%
Change 5-day change 1-year change 3-year change Capi.($)
-0.04%-.--% - - 1.4TCr
+0.83%+3.19%+41.49%+103.56% 1,05100Cr
+1.93%+2.11%+37.08%+65.09% 63TCr
+1.49%+5.19%+19.94%+85.69% 49TCr
+2.26%+0.90%+69.32%+40.53% 36TCr
+1.45%+3.50%+23.29%+41.62% 34TCr
+1.17%+2.37%+13.47%+33.64% 27TCr
+0.89%+1.08%-6.13%+9.29% 25TCr
+1.82%+2.94%+42.99%+52.95% 22TCr
+2.77%+4.44%+29.01%+98.99% 19TCr
Average +1.46%+2.53%+30.05%+59.04% 42.26TCr
Weighted average by Cap. +1.46%+2.44%+33.36%+69.01%
Logo Intra-Cellular Therapies, Inc.
Intra-Cellular Therapies, Inc. is a biopharmaceutical company focused on the development and commercialization of small molecule drugs that address underserved medical needs primarily in psychiatric and neurological disorders. The Company’s product, CAPLYTA (lumateperone), is an oral, once daily atypical antipsychotic approved in adults for the treatment of schizophrenia and the treatment of depressive episodes associated with bipolar I or II disorder (bipolar depression) as monotherapy and as adjunctive therapy with lithium or valproate. Lumateperone is also being studied for the treatment of major depressive disorder, and other psychiatric and neurological disorders. Its pipeline includes several product candidates in clinical development and additional product candidates in non-clinical testing, such as the ITI-1284-ODT-SL program, Phosphodiesterase type I inhibitor (PDE1) program, ITI-333 program, and ITI-1500 Non-Hallucinogenic Psychedelic program.
Employees
860
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
  1. Stock Market
  2. Stocks
  3. ITCI Stock